Similarly, quercetagitrin enhanced the inhibitory effects of defactinib and ponatinib on the expression of CDK7/9, Ki67, and LYVE1 in primary tumor tissues (Supplementary Fig. 21b) and the activation and expression of Yamanaka transcription factors in lymph nodes (Supplementary Fig. 21c). Here, LYVE1 is linked to neoplasm.